Abstract 293P
Background
OXN PR, a fixed dose combination of opioid and peripherally-acting mu-opioid antagonist, offers analgesia while reducing opioid-induced constipation (OIC). Few have studied OXN vs other strong opioids for impact on bowel function, safety and QoL in patients with CP.
Methods
Systematic review of literature from PubMed and EMBASE that evaluated analgesia, bowel function, adverse events (AE) and QoL after OXN PR or oral oxycodone (OXY)/morphine/tapentadol PR, or transdermal fentanyl, in adults with moderate-severe CP. Data for outcomes were extracted from publications or clinical study reports.
Results
4 RCTs (OXN vs OXY) were found; no RCT compared OXN vs other strong opioids. Analgesia and safety were comparable with OXN or OXY, except for nausea that was less frequent with OXN (Odds ratio: 0.51 [0.26, 0.97]). Most AEs related to OXN and OXY were mild-moderate severity; most common were gastrointestinal disorders. Improved bowel function (BFI, PAC-SYM) was observed with OXN vs OXY (Table). QoL was comparable with OXN or OXY (Global health status, mean difference: 0.5 [-4.7, 5.7]). Table: 293P
Descriptive findings for bowel function
RCTs | Findings | OXN vs OXY | |
BFI | |||
Scores over 4 weeks | 2 | Δ mean (% improvement)† | RCT 1: -25.1 (39.2%) vs -13.6 (21.7%) RCT 2: -36.0 (50.7%) vs -25.0 (36.8%) |
Score comparison at week 4 | 1 | LS mean difference (SE) | -11.1 (4.00) |
95% CI‡ | [-19.0, -3.2] | ||
P value‡ | 0.006 | ||
PAC-SYM | |||
Total score | 1 | Δ mean (% improvement)† | -7.0 (40.3%) vs -2.7 (15.1%) |
P-value§ | 0.0014 | ||
Symptom frequency | 1 | Δ mean (% improvement)† | -1.1 (41.9%) vs -0.3 (12.9%) |
P value§ | <0.001 |
†baseline to week 4 ‡adjusted for baseline using ANCOVA model. §between-group difference; derived from summary statistics LS, least squared.
Conclusions
Systematic review found only direct comparisons of OXN vs OXY in RCTs of CP. OXN provided similar analgesia and safety to OXY for CP with less nausea and improved bowel function, in terms of constipation symptoms. OXN is a valuable analgesic option in patients with OIC or nausea from cancer itself or anticancer treatment. Although limited, this meta-analysis confirms existing evidence on OXN’s efficacy and tolerability in patients with moderate-severe CP and highlights that few data on OXN in CP is available.
Clinical trial identification
Editorial acknowledgement
Editorial assistance was provided by Wei Yi Kwok and Geraldine Toh from Tech Observer Asia Pacific Pte Ltd.
Legal entity responsible for the study
Mundipharma Singapore Holding Pte Ltd.
Funding
Mundipharma Singapore Holding Pte Ltd.
Disclosure
S.H. Ahmedzai: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Mundipharma. L. Langenhoven: Advisory/Consultancy, Speaker Bureau/Expert testimony: Mundipharma. C. Minnaert, Y. Hadjiat: Full/Part-time employment: Mundipharma. All other authors have declared no conflicts of interest.
Resources from the same session
143P - Lymph nodes metastasis is the most important factor associated with pattern of recurrence following curative resection of gastric adenocarcinoma
Presenter: Fu-Hai Wang
Session: e-Poster Display Session
144P - Clinical implication of DNA damage response gene in patients with stage II or III gastric cancer
Presenter: In Gyu Hwang
Session: e-Poster Display Session
145P - A nomogram for predicting the benefit of adjuvant chemotherapy after resection in patients with Borrmann type IV gastric cancer
Presenter: Qing-Zhu Qiu
Session: e-Poster Display Session
146P - Red cell distribution width and mean corpuscular volume ratio as a promising new marker for chemotherapy effects in remnant gastric cancer: An analysis of a multi-institutional database
Presenter: Kai-Xiang Xu
Session: e-Poster Display Session
147P - Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?
Presenter: Hayato Watanabe
Session: e-Poster Display Session
148P - MCV-the ideal answer to predict the prognosis of remnant gastric cancer: An analysis from a multi-institutional database
Presenter: Kai Weng
Session: e-Poster Display Session
149P - Molecular and clinical characteristics of patients with resectable gastric cancer
Presenter: Zhi Zheng
Session: e-Poster Display Session
150P - Real-world assessment of the treatment patterns associated with unresectable advanced and metastatic gastric cancer in China
Presenter: Xiao Sun
Session: e-Poster Display Session
151P - Treatment patterns, healthcare resource use, economic and survival outcomes associated with unresectable advanced metastatic gastric cancers in Taiwan
Presenter: Chee Jen Chang
Session: e-Poster Display Session
152P - ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Presenter: Koji Kase
Session: e-Poster Display Session